AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, ...

Proficio Capital Partners just added 2,230 shares of AbbVie, giving its portfolio a pharma-flavored boost worth $1.18 million ...

AbbVie’s stock dipped 0.29% to close at $213.85, a minor move compared to the S&P 500's steeper 1.07% drop. Despite this ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation.

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...